Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD22 Antikörper (PE)

Dieses Anti-CD22-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von CD22 in FACS und IF. Geeignet für Human.
Produktnummer ABIN1106082

Kurzübersicht für CD22 Antikörper (PE) (ABIN1106082)

Target

Alle CD22 Antikörper anzeigen
CD22 (CD22 Molecule (CD22))

Reaktivität

  • 197
  • 61
  • 26
  • 5
  • 3
  • 2
  • 2
  • 1
Human

Wirt

  • 130
  • 81
  • 17
  • 3
Maus

Klonalität

  • 168
  • 61
  • 1
Monoklonal

Konjugat

  • 126
  • 17
  • 13
  • 9
  • 7
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser CD22 Antikörper ist konjugiert mit PE

Applikation

  • 143
  • 107
  • 56
  • 51
  • 48
  • 36
  • 29
  • 21
  • 11
  • 11
  • 5
  • 4
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), Immunofluorescence (IF)

Klon

B-ly8
  • Spezifität

    Clone B-ly8 produces mouse IgG1 immunoglobulins directed against CD22, molecular weight 130-140 kDa.

    Aufreinigung

    Affinity chromatography

    Isotyp

    IgG1
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Buffer

    0.01 M sodium phosphate, 0.15 M NaCl, pH 7.3, 0.2 % BSA, 0.09 % sodium azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C

    Informationen zur Lagerung

    Store the antibody undiluted at 2-8 °C. Fluorochrome labelled product is photosensitive and should be protected from light.
  • Target

    CD22 (CD22 Molecule (CD22))

    Andere Bezeichnung

    CD22

    Hintergrund

    CD22 is detected in the cytoplasm early in B cell development (late pro-B cell stage), appears on the cell surface simultaneously with surface IgD, and is found on most mature B cells. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via surface Ig increases CD22 expression [1]. It is more strongly expressed on prolymphocytic leukemia and HCL than in chronic lymphocytic leukemia. B cell lineage ALL express membrane and cytoplasmic CD22. CD22 forms a loose complex with the BcR cell antigen receptor (BcR) [2]. The cytoplasmic domain is tyrosine phosphorylated upon ligation of the BCR and associates via SH2 domains with the tyrosine phosphatase SHP-1, the tyrosine kinase Syk and phospholipase C-g1 [3,4]. CD22 down-modulates the B cell activation threshold, presumably through its association with SHP-1 and other signaling molecules [2,3]. Mice deficient in CD22 show exaggerated antibody responses to antigen and have raised levels of autoantibodies [1,5]. CD22 can also mediate cell adhesion through its interaction with cell surface molecules bearing the appropriate sialoglycoconjugates, but only when these conjugates are not on the CD22 bearing cell itself [2,6].Synonyms: B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2

    Gen-ID

    933

    NCBI Accession

    NP_001172028

    UniProt

    P20273
Sie sind hier:
Chat with us!